| Income Statement | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 |
|---|---|---|---|---|
| Services | 0 | 0 | 0 | 0* |
| Cost of services | 0 | 0 | NaN | NaN |
| Gross profit | 0 | 0 | NaN | NaN |
| Research and development expense | NaN | 0 | NaN | 0* |
| General and administrative expenses | 162,763 | 72,963 | 64,002 | 162,286.25* |
| Total operating expenses | 162,763 | 72,963 | 64,002 | 162,286.25* |
| Loss from operations | -162,763 | -72,963 | -64,002 | -162,286.25* |
| Capital loss | NaN | 0 | NaN | 0* |
| Financial loss, net | NaN | NaN | NaN | 10,571.25* |
| Financial income (loss), net | 8,598 | 28,865 | -49,717 | NaN |
| Net (loss) | -154,165 | -44,098 | -113,719 | -172,857.5 |
| Profit (loss) from available for sale assets | NaN | 0 | 0 | NaN |
| Total comprehensive income (loss) | -154,165 | -44,098 | -113,719 | -172,857.5 |
| Basic EPS | 0 | 0 | 0 | -0.001 |
| Diluted EPS | 0 | 0 | 0 | -0.001 |
| Basic Average Shares | 1,318,594,182 | 931,015,714 | 732,857,211 | 198,239,676 |
| Diluted Average Shares | 1,318,594,182 | 931,015,714 | 732,857,211 | 198,239,676 |
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)